American Renal Associates Holdings Inc. (NYSE:ARA) was downgraded by research analysts at Goldman Sachs Group Inc. from a “neutral” rating to a “sell” rating in a report issued on Monday.

A number of other research firms also recently issued reports on ARA. Zacks Investment Research downgraded American Renal Associates Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th. Leerink Swann reiterated a “buy” rating on shares of American Renal Associates Holdings in a report on Thursday, August 11th. Barclays PLC restated a “buy” rating and set a $31.00 price target on shares of American Renal Associates Holdings in a report on Thursday, August 18th. Bank of America Corp. restated a “buy” rating and set a $35.00 price target on shares of American Renal Associates Holdings in a report on Monday, August 22nd. Finally, Wells Fargo & Co. restated a “buy” rating on shares of American Renal Associates Holdings in a report on Sunday, September 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $29.50.

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

American Renal Associates Holdings (NYSE:ARA) opened at 24.10 on Monday. The firm’s 50-day moving average is $18.70 and its 200 day moving average is $23.19. The company’s market cap is $743.92 million. American Renal Associates Holdings has a 12-month low of $16.86 and a 12-month high of $29.65.

American Renal Associates Holdings (NYSE:ARA) last posted its quarterly earnings data on Thursday, November 10th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. The business earned $192.96 million during the quarter, compared to the consensus estimate of $189.73 million. American Renal Associates Holdings had a return on equity of 55.06% and a net margin of 1.92%. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. On average, equities analysts expect that American Renal Associates Holdings will post $0.99 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System boosted its stake in American Renal Associates Holdings by 1.1% in the third quarter. California State Teachers Retirement System now owns 18,504 shares of the company’s stock valued at $338,000 after buying an additional 200 shares during the period. Bank of New York Mellon Corp boosted its stake in American Renal Associates Holdings by 20.3% in the third quarter. Bank of New York Mellon Corp now owns 23,524 shares of the company’s stock valued at $430,000 after buying an additional 3,971 shares during the period. Acrospire Investment Management LLC acquired a new stake in American Renal Associates Holdings during the second quarter valued at approximately $130,000. American International Group Inc. acquired a new stake in American Renal Associates Holdings during the second quarter valued at approximately $146,000. Finally, Nationwide Fund Advisors acquired a new stake in American Renal Associates Holdings during the second quarter valued at approximately $166,000. Hedge funds and other institutional investors own 85.45% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

5 Day Chart for NYSE:ARA

Receive News & Stock Ratings for American Renal Associates Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc. and related stocks with our FREE daily email newsletter.